Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS)
CUSIP: 501147102
Q2 2018 13F Holders as of 30 Jun 2018
- Type / Class
- Equity / Common Stock, $0.00001 par value ("Common Stock")
- Shares outstanding
- 29,463,330
- Total 13F shares
- 2,390,244
- Share change
- -686,011
- Total reported value
- $35,543,000
- Price per share
- $14.87
- Number of holders
- 16
- Value change
- -$7,828,421
- Number of buys
- 9
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 501147102?
CUSIP 501147102 identifies KRYS - Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 501147102:
Top shareholders of KRYS - Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
4.1%
|
1,200,000
|
$12,108,000 | — | 31 Mar 2018 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.7%
|
496,071
|
$5,005,000 | — | 31 Mar 2018 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
300,000
|
$3,027,000 | — | 31 Mar 2018 | |
| Knoll Capital Management, LLC |
13F
|
Company |
1%
|
300,000
|
$3,027,000 | — | 31 Mar 2018 | |
| Tourbillon Capital Partners, L.P. |
13F
|
Company |
0.86%
|
252,348
|
$2,546,000 | — | 31 Mar 2018 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.68%
|
200,000
|
$2,018,000 | — | 31 Mar 2018 | |
| Artal Group S.A. |
13F
|
Company |
0.51%
|
150,000
|
$1,514,000 | — | 31 Mar 2018 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.51%
|
149,109
|
$1,505,000 | — | 31 Mar 2018 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.06%
|
17,198
|
$174,000 | — | 31 Mar 2018 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.03%
|
7,433
|
$75,000 | — | 31 Mar 2018 | |
| KBC Group NV |
13F
|
Company |
0.01%
|
2,225
|
$22,000 | — | 31 Mar 2018 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.01%
|
1,871
|
$19,000 | — | 31 Mar 2018 |
Institutional Holders of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) as of Q2 2018
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2018 vs Q1 2018 Across Filers
| Investor | Q1 2018 Shares | Q2 2018 Shares | Share Diff | Share Chg % | Q1 2018 Value $ | Q2 2018 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.